MedPath

Zhejiang Yatai Pharmaceutical Co.,Ltd.

🇨🇳China
Ownership
-
Established
2001-12-31
Employees
528
Market Cap
-
Website
www.ytyaoye.com
Introduction

The company, formerly known as Zhejiang Asia Pacific Pharmaceutical Factory, was founded in 1989 and is now located at No. 36 Nanbin West Road, Lihai Street, Yuecheng District, Shaoxing City, Zhejiang Province. The shareholding system reform was completed in December 2001, and officially listed on the Shenzhen Stock Exchange on March 16, 2010. Currently, the company's products cover several major sectors such as chemical preparations, chemical raw materials, and drug research and development. Ningbo Fubon Holding Group is a large private group integrating commerce, real estate, energy, sports and other industries, and has been listed as a top 500 enterprise over the years. On April 15, 2022, Fubon Group joined Asia Pacific Pharmaceutical as the controlling shareholder, and Asia Pacific Pharmaceutical became a member of the big health industry chain under Fubon Group. The company's main business is pharmaceutical manufacturing, including R&D, production and sales of chemical agents. The main customers are pharmaceutical businesses, distribution companies and medical institutions. The company's main products are antibiotics, antiviral, cardiovascular, digestive, antipyretic and analgesic chemicals. Corporate honors: Enterprise Credit Rating AAA; Shaoxing County Advanced Tax Payment Unit; Shaoxing County Advanced Tax Payment Unit; Shaoxing County Family Planning Advanced Unit; Shaoxing County Enterprise Credit Rating AAA, etc.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

116

NMPA:116

Drug Approvals

Tigecycline for Injection

Product Name
注射用替加环素
Approval Number
国药准字H20253298
Approval Date
Jan 24, 2025
NMPA

Cefmetazole Sodium for Injection

Product Name
注射用头孢美唑钠
Approval Number
国药准字H20247311
Approval Date
Dec 11, 2024
NMPA

Cefmetazole Sodium for Injection

Product Name
注射用头孢美唑钠
Approval Number
国药准字H20247312
Approval Date
Dec 11, 2024
NMPA

Esomeprazole Sodium for Injection

Product Name
注射用艾司奥美拉唑钠
Approval Number
国药准字H20203030
Approval Date
Sep 13, 2024
NMPA

Ceftizoxime Sodium for Injection

Product Name
注射用头孢唑肟钠
Approval Number
国药准字H20247191
Approval Date
Aug 15, 2024
NMPA

Ceftizoxime Sodium for Injection

Product Name
注射用头孢唑肟钠
Approval Number
国药准字H20247192
Approval Date
Aug 15, 2024
NMPA

Bezafibrate Tablets

Product Name
苯扎贝特片
Approval Number
国药准字H20093503
Approval Date
Mar 1, 2024
NMPA

Cefamandole Nafate for Injection

Product Name
注射用头孢孟多酯钠
Approval Number
国药准字H20143231
Approval Date
Mar 1, 2024
NMPA

Terazosin Hydrochloride Tablets

Product Name
盐酸特拉唑嗪片
Approval Number
国药准字H20084527
Approval Date
Sep 4, 2023
NMPA

Cefoxitin Sodium for Injection

Product Name
注射用头孢西丁钠
Approval Number
国药准字H20084336
Approval Date
Jun 8, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 12
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.